Novartis Acquires Excellergy for Up to $2 Billion in Major Deal

Novartis acquired US-based biotech firm Excellergy for up to $2 billion to expand its immunology pipeline. This significant deal highlights Novartis's focus on next-generation treatments. The purchase further bolsters Novartis's position as a major player in the pharmaceutical industry.

NVS announced a deal to acquire US-based biotech firm Excellergy for up to $2 billion in upfront and milestone payments, marking its second multi-billion dollar acquisition in a single week. The deal adds Exl-111, a Phase 1 half-life extended anti-IgE antibody designed to dissociate receptor-bound IgE, a novel mechanism that could support earlier symptom relief across food allergy, asthma, and chronic urticaria.

The acquisition builds on Novartis's established expertise in IgE biology and allergy treatment, expanding its immunology pipeline at a time when the allergy therapeutics market is seeing renewed interest from large pharma. The transaction is expected to close in the second half of 2026, subject to regulatory approval.

For NVS investors, the deal signals continued aggressive capital deployment toward pipeline growth. The milestone-based payment structure limits near-term financial risk, but the Phase 1 stage of the lead asset means meaningful revenue contribution is likely years away. The market will be watching closely for early clinical readouts to validate the premium price tag.